Cortechs.AI Receives NIH Grant to Develop ARIA Detection Software

Cortechs.ai announced it has received a three-year, multimillion dollar NIH grant to support the development of additional analysis software to automatically detect and quantify the Amyloid Related Imaging Abnormalities (ARIA) throughout the treatment of Alzheimer disease patients. ARIA imaging is used to monitor the effects of the therapeutic intervention and to improve patient management.

"Cortechs.ai is not only committed to driving commercial excellence with our product portfolio, but also we are equally dedicated to driving research that delivers key values to patients and clinicians alike. This ARIA grant signifies our commitment", says Kyle Frye, CEO.

Cortechs.ai pioneered NeuroQuant, a volumetric analysis software solution for various neurological disorders, and the latest 510()k-pending NeuroQuant update supports identification and evaluation of cerebral microhemorrhages and vasogenic edema in patients with ARIA.

Dr Aziz Ulug, the principal investigator of this study, says "With the recent FDA approval of drugs that target amyloid deposits, brain imaging becomes an indispensable tool to monitor treatment related changes and abnormalities in Alzheimer patients undergoing therapy. Our new research grant will enhance our existing products and continue our commitment for helping patients and families coping with Alzheimer disease."